Spyre Therapeutics (SYRE) Assets Average: 2016-2025
Historic Assets Average for Spyre Therapeutics (SYRE) over the last 10 years, with Sep 2025 value amounting to $521.7 million.
- Spyre Therapeutics' Assets Average rose 21.73% to $521.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $521.7 million, marking a year-over-year increase of 21.73%. This contributed to the annual value of $475.2 million for FY2024, which is 130.11% up from last year.
- Per Spyre Therapeutics' latest filing, its Assets Average stood at $521.7 million for Q3 2025, which was down 5.88% from $554.3 million recorded in Q2 2025.
- Spyre Therapeutics' Assets Average's 5-year high stood at $589.1 million during Q1 2025, with a 5-year trough of $61.8 million in Q1 2023.
- Its 3-year average for Assets Average is $381.3 million, with a median of $428.6 million in 2024.
- In the last 5 years, Spyre Therapeutics' Assets Average crashed by 40.63% in 2022 and then skyrocketed by 571.10% in 2024.
- Spyre Therapeutics' Assets Average (Quarterly) stood at $119.5 million in 2021, then slumped by 31.92% to $81.4 million in 2022, then spiked by 237.49% to $274.6 million in 2023, then surged by 87.49% to $514.8 million in 2024, then increased by 21.73% to $521.7 million in 2025.
- Its Assets Average was $521.7 million in Q3 2025, compared to $554.3 million in Q2 2025 and $589.1 million in Q1 2025.